Hives lasting more than six weeks need a different approach.
Chronic spontaneous urticaria is a mast-cell driven, immune-dysregulated disease — not just an allergy. When standard antihistamines are not enough, targeted advanced options exist.
Daily impact
Persistent hives disrupt sleep, work and confidence. Many patients silently normalize daily symptoms or repeated steroid courses — a pattern that modern evaluation can change.
When to seek specialized evaluation
- Hives most days for more than 6 weeks
- Symptoms despite up-dosed second-generation antihistamines
- Frequent oral steroid use to control flares
- Significant impact on sleep or daily activities
- Associated angioedema (lip / eye / face swelling)
- Inducible patterns (cold, pressure, cholinergic)
How we evaluate
We characterize spontaneous vs inducible patterns, assess control with validated tools (UCT, UAS), review antihistamine response, screen for autoimmune and thyroid associations, and structure the next therapeutic step.
Advanced treatment options
Beyond up-dosed antihistamines, modern care includes biologic therapy — anti-IgE (omalizumab) and anti-IL-4Rα (dupilumab, FDA-approved for chronic spontaneous urticaria in 2025) — and targeted immunomodulators in selected cases.
Chronic urticaria sits within systemic allergic inflammation.
Persistent hives often occur alongside other type 2 and mast-cell driven conditions. Mapping the full inflammatory pattern helps identify advanced therapies that address shared biology.